ArticleJournal of experimental & clinical cancer research : CR2020

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.

Liangning Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.